February 10, 2026 Sweden
During the weekly life science breakfast seminar “Lilla lördag”, Diamyd Medical’s CEO Ulf Hannelius addressed the topic Precision Immunotherapy in type 1 diabetes. The presentation included insights from the company’s ongoing Phase 3 clinical trial evaluating retogatein (rhGAD65), ahead of an interim readout expected in March 2026.
The event was recorded by Flemingsberg Science Foundation in Flemingsberg on February 5, 2026.
|
February 9, 2026 USA
Diamyd Medical has received a Notice of Allowance from the U.S. Patent Office for a patent covering the intralymphatic administration of its diabetes drug candidate retogatein (rhGAD65). Once granted, the patent is expected to provide patent protection until 2035 and further strengthen the company’s intellectual property position in the U.S., aligned with the ongoing Phase 3 study, with an interim efficacy readout anticipated by the end of March 2026. Read the article here
|
February 4, 2026 Sweden
In an interview with Ventures Accelerated, Ulf Hannelius, CEO of Diamyd Medical, outlines the company’s transition from long-term strategy to a results-driven phase as its pivotal Phase 3 study advances toward the upcoming interim efficacy readout in March 2026. Read the article and watch the video here
|
January 28, 2026 Sweden
Diamyd Medical´s vd Ulf Hannelius presenterar bolagets kvartalsrapport och nuvarande status i bolaget.
Rapporten publicerades den 28 januari 2026. Producerat i samarbete med BioStock, moderator Cecilia Hallström.
|
January 26, 2026 Sweden
Diamyd Medical has strengthened its manufacturing platform through an expanded collaboration with APL in Umeå and a strategic partnership with NorthX Biologics in Matfors. The alliances integrate complementary expertise across the biopharmaceutical value chain, supporting the transition from late-stage clinical development to potential commercial production. At the same time, the initiative reinforces northern Sweden’s growing role as a center for advanced life-science manufacturing. Read the article here
|